A
Andreas Viardot
Researcher at University of Ulm
Publications - 166
Citations - 8997
Andreas Viardot is an academic researcher from University of Ulm. The author has contributed to research in topics: Blinatumomab & Rituximab. The author has an hindex of 35, co-authored 143 publications receiving 7645 citations. Previous affiliations of Andreas Viardot include University of Kansas Hospital & University of Münster.
Papers
More filters
Journal ArticleDOI
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf C. Bargou,Eugen Leo,Gerhard Zugmaier,Matthias Klinger,Mariele Goebeler,Stefan Knop,Richard Noppeney,Andreas Viardot,Georg Hess,Martin Schuler,Hermann Einsele,Christian Brandl,Andreas Wolf,Petra Kirchinger,Petra Klappers,Margit Schmidt,Gert Riethmüller,Carsten Reinhardt,Patrick A. Baeuerle,Peter Kufer +19 more
TL;DR: The clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells, is reported on.
Journal ArticleDOI
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal,Ajay K. Gopal,Brad S. Kahl,Sven de Vos,Nina D. Wagner-Johnston,Stephen J. Schuster,Wojciech Jurczak,Ian W. Flinn,Christopher R. Flowers,Peter Martin,Andreas Viardot,Kristie A. Blum,Andre Goy,Andrew Davies,Pier Luigi Zinzani,Martin Dreyling,Dave Johnson,Langdon L. Miller,Leanne Holes,Daniel Li,Roger Dansey,Wayne R. Godfrey,Gilles Salles +22 more
TL;DR: In this single-group, open-label, phase 2 study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment.
Journal ArticleDOI
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp,Peter Kufer,Nicola Gökbuget,Mariele Goebeler,Matthias Klinger,Svenja Neumann,Heinz-A. Horst,Thorsten Raff,Andreas Viardot,Mathias Schmid,Matthias Stelljes,Markus Schaich,Evelyn Degenhard,Rudolf Köhne-Volland,Monika Brüggemann,Oliver G. Ottmann,Heike Pfeifer,Thomas Burmeister,Dirk Nagorsen,Margit Schmidt,Ralf Lutterbuese,Carsten Reinhardt,Patrick A. Baeuerle,Michael Kneba,Hermann Einsele,Gert Riethmüller,Dieter Hoelzer,Gerhard Zugmaier,Ralf C. Bargou +28 more
TL;DR: T cells engaged by blinatumomab seem capable of eradicating chemotherapy-resistant tumor cells that otherwise cause clinical relapse in patients with MRD-positive B-lineage ALL after intensive chemotherapy.
Journal ArticleDOI
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp,Nicola Gökbuget,Gerhard Zugmaier,Petra Klappers,Matthias Stelljes,Svenja Neumann,Andreas Viardot,Reinhard Marks,H. Diedrich,Christoph Faul,Albrecht Reichle,Heinz-August Horst,Monika Brüggemann,Dorothea Wessiepe,Chris Holland,Shilpa Alekar,Noemi Mergen,Hermann Einsele,Dieter Hoelzer,Ralf C. Bargou +19 more
TL;DR: The data support further investigation of blinatumomab for the treatment of adult patients with relapsed or refractory ALL in a larger confirmatory study.
Journal ArticleDOI
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp,Nicola Gökbuget,Gerhard Zugmaier,Evelyn Degenhard,Marie-Elisabeth Goebeler,Matthias Klinger,Svenja Neumann,Heinz A. Horst,Thorsten Raff,Andreas Viardot,Matthias Stelljes,Markus Schaich,Rudolf Köhne-Volland,Monika Brüggemann,Oliver G. Ottmann,Thomas Burmeister,Patrick A. Baeuerle,Dirk Nagorsen,Margit Schmidt,Hermann Einsele,Gert Riethmüller,Michael Kneba,Dieter Hoelzer,Peter Kufer,Ralf C. Bargou +24 more
TL;DR: It is concluded that blinatumomab can induce long-lasting complete remission in B-lineage ALL patients with persistent or recurrent MRD and of the subgroup of 6 Philadelphia chromosome-negative MRD responders with no further therapy after blinumomab, 4 are in ongoing hematologic and molecular remission.